EC Microbiology

Volume 19 Issue 9 - 2023

Effects of D-Psicose on Growth and Hyphal Development of Candida albicans

Qianying Li1, Kosuke Kataoka DDS, PhD1,2*, Hideki Yoshimatsu1 and Tatsuro Miyake1

1Department of Preventive and Community Dentistry, Graduate School of Dentistry, Osaka Dental University, Hirakata, Osaka, Japan
2Department of Oral Health Science and Social Welfare, Graduate School of Oral Sciences, Tokushima University, Tokushima, Tokushima, Japan
*Corresponding Author: Kosuke Kataoka DDS, PhD, Department of Oral Health Science and Social Welfare, Graduate School of Oral Sciences, Tokushima University, 3-8-15 Kuramoto-cho, Tokushima, Tokushima, Japan.
Received: September 04, 2023; Published: September 29, 2023



D-Psicose (C6H12O6), also referred to as D-allulose, is a well-known rare sugar that exists as a monosaccharide in nature and has approximately 70% of the sweetness of sucrose and no calories. In recent years, D-psicose has been reported to have a variety of physiological effects in animals and humans, such as anti-inflammatory and antioxidant effects. In this study, we investigated the effect of D-psicose on the growth of Candida albicans (Ca) - a heterotrophic fungus that is commonly found in humans and which is a frequent etiological agent of candidiasis. We observed morphological changes using two microscopic techniques. Furthermore, we analyzed the expression of virulence-related genes in Ca when cultured in liquid medium containing 4% D-psicose at 37°C under aerobic conditions using quantitative reverse transcription-PCR (qRT-PCR) methods. Compared to culturing in liquid Sabouraud’s medium containing 4% D-glucose (SM), Ca took longer to reach the stationary growth phase in liquid peptone medium containing 4% D-psicose (PM). Further, in the methyl thiazolyl tetrazolium (MTT; 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay, Ca strain ATCC 10261 cultured in liquid PM showed a significant reduction in metabolic activity (approximately 80%) when compared culturing in liquid SM, suggesting that D-psicose reduces Ca viability. Interestingly, microscopic analysis revealed the inhibition of hyphal development in Ca cultured in liquid PM at 37°C. In addition, qRT-PCR showed downregulation of the expression of virulence-related genes HWP1 and PLB1 in Ca cultured in liquid PM compared to Ca cultured in liquid SM. Taken together, these results show that D-psicose weakens the growth and inhibits hyphal development of Ca, and strongly suggest that D-psicose suppresses Ca morphogenesis and biofilm formation. By substituting sugar (glucose) with D-psicose in the daily diet, it may be possible to delay the onset of candidiasis in the body and oral cavity of the aged and immunocompromised patients, and thus, to reduce the frequency of dental visits for maintaining the oral cavity and dental prosthesis. This is the first report regarding the impact of D-psicose, a rare sugar, on Ca.

 Keywords: D-Psicose; Rare Sugar; Candida albicans; Growth; Hyphae; HWP1; PLB1

  1. Matsuo T., et al. “D-psicose is a rare sugar that provides no energy to growing rats”. Journal of Nutritional Science and Vitaminology (Tokyo) 48 (2002): 77-80.
  2. Izumori K. “Izumoring: A strategy for bioproduction of all hexoses”. Journal of Biotechnology 124 (2006): 717-722.
  3. Takeshita K., et al. “Mass production of D-psicose from D-fructose by a continuous bioreactor system using immobilized D-tagatose 3-epimerase”. Journal of Bioscience and Bioengineering 90 (2000): 453-455.
  4. Zhang W., et al. “Production of D-allulose from D-glucose by Escherichia coli transformant cells co-expressing D-glucose isomerase and D-psicose 3-epimerase genes”. Journal of the Science of Food and Agriculture 97 (2017): 3420-3426.
  5. Yang J., et al. “Development of food-grade expression system for D-allulose 3-epimerase preparation with tandem isoenzyme genes in Corynebacterium glutamicum and its application in conversion of cane molasses to D-allulose”. Biotechnology and Bioengineering 116 (2019): 745-756.
  6. Mu W., et al. “Recent advances on application and biotechnological production of D-psicose”. Applied Microbiology and Biotechnology 94 (2012): 1461-1467.
  7. Hossain MA., et al. “Rare sugar D-psicose improves insulin sensitivity and glucose tolerance in type 2 diabetes Otsuka Long-Evans Tokushima Fatty (OLETF) rats”. Biochemical Biophysical Research Communications 405 (2011): 7-12.
  8. Kimura T., et al. “d-Allulose enhances postprandial fat oxidation in healthy humans”. Nutrition 43-44 (2017): 16-20.
  9. Matsuo T and Izumori K. “Effects of dietary D-psicose on diurnal variation in plasma glucose and insulin concentrations of rats”. Bioscience, Biotechnology and Biochemistry 70 (2006): 2081-2085.
  10. Matsuo T and Izumori K. “D-psicose inhibits intestinal a-glucosidase and suppresses the glycemic response after ingestion of carbohydrates in rats”. Journal of Clinical Biochemistry and Nutrition 45 (2009): 202-206.
  11. Iida T., et al. “Reduction of abdominal fat accumulation in rats by 8-week ingestion of a newly developed sweetener made from high fructose corn syrup”. Food Chemistry 138 (2013): 781-785.
  12. Bilal M., et al. “Metabolic engineering pathways for rare sugars biosynthesis, physiological functionalities, and applications-a review”. Critical Reviews in Food Science and Nutrition 58 (2018): 2768-2778.
  13. Kim SE., et al. “D-psicose, a sugar substitute, suppresses body fat deposition by altering networks of inflammatory response and lipid metabolism in C57BL/6J-ob/ob mice”. Journal of functional Foods 28 (2017): 265-274.
  14. Takata MK., et al. “Neuroprotective effect of D-psicose on 6-hydroxydopamine-induced apoptosis in rat pheochromocytoma (PC12) cells”. Journal of Bioscience and Biotechnology 100 (2005): 511-516.
  15. Kanasaki A., et al. “D-allulose alters serum cholesterol levels partly via reducing serum pcsk9 levels in hamsters”. Atherosclerosis 287 (2019): e201.
  16. Natsume Y., et al. “Investigation of D-allulose effects on high-sucrose diet-induced insulin resistance via hyper insulinemic-euglycemic clamps in rats”. Heliyon 7 (2021): e08013.
  17. MacFarlane TW. “Ecology and epidemiology of Candida”. In Oral Candidosis. Edited by L.P. Samaranayake and T. W. McFarlane. London: Wright (1990): 21-46.
  18. McCullough MJ., et al. “Candida albicans: a review of its history, taxonomy, epidemiology, virulence attributes, and methods of strain differentiation”. International Journal of Oral and Maxillofacial Surgery 25 (1996): 136-144.
  19. Nettleman MD., et al. “Secular trends in the epidemiology of nosocomial fungal infection at a teaching hospital in Taiwan, 1981 to 1993”. Infection Control and Hospital Epidemiology 18 (1997): 369-375.
  20. Edmond MB., et al. “Nosocomial bloodstream infections in United States hospitals: a three-year analysis”. Clinical Infectious Diseases 29 (1999): 239-244.
  21. Ruan S-Y., et al. “Invasive Candidiasis: an overview from Taiwan”. Journal of the Formosan Medical Association 108 (2009): 443-451.
  22. Hirota K., et al. “Pathogenic factors in Candida biofilm-related infectious diseases”. Journal of Applied Microbiology 122 (2017): 321-330.
  23. Calderone RA and Fonzi WA. “Virulence factors of Candida albicans”. Trends in Microbiology 9 (2001): 327-335.
  24. Sudbery PE. “Growth of Candida albicans hyphae”. Nature Reviews Microbiology 9 (2011): 737-748.
  25. Cottier F and Mühlshlegel FA. “Sensing the environment: Response of Candida albicans to the X factor”. FEMS Microbiology Letters 295 (2009): 1-9.
  26. Lo HJ., et al. “Nonfilamentous C. albicans mutants are avirulent”. Cell 90 (1997): 939-949.
  27. Saville SP., et al. “Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection”. Eukaryotic Cell 2 (2003): 1053-1060.
  28. Ten Cate JM., et al. “Molecular and cellular mechanisms that lead to Candida biofilm formation”. Journal of Dental Research 88 (2009): 105-115.
  29. Moyes DL., et al. “Candidalysin is a fungal peptide toxin critical for mucosal infection”. Nature 532 (2016): 64-68.
  30. Naglik JR., et al. “Candida albicans HWP1 gene expression and host antibody responses in colonization and disease”. Journal of Medical Microbiology 55 (2006): 1323-1327.
  31. Samaranayake YH., et al. “Phospholipase B enzyme expression is not associated with other virulence attributes in Candida albicans isolates from patients with human immunodeficiency virus infection”. Journal of Medical Microbiology 54 (2005): 583-593.
  32. Schaller M., et al. “Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity”. Molecular Microbiology 29(1998): 605-615.
  33. Tsang PW-K., et al. “Purpurin suppresses Candida albicans biofilm formation and hyphal development”. PLoS One 7 (2012): e50866.
  34. Harada M., et al. “D-allose and D-psicose reinforce the action of metronidazole on trichomonad”. Parasitology Research 110 (2012): 1565-1567.
  35. Hu L., et al. “Characterization of oral candidiasis and the Candida species profile in patients with oral mucosal diseases”. Microbial Pathogenesis 134 (2019): 103575.
  36. Jin Y., et al. “Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars”. Archives of Oral Biology 49 (2004): 789-798.
  37. Ghezzi EM. “Developing pathways for oral care in elders: evidence-based interventions for dental caries prevention in dentate elders”. Gerodontology 31 (2014): 31-36.
  38. Han P., et al. “Dry mouth: A critical topic for older adult patients”. Journal of Prosthodontic Research 61 (2015): 6-19.
  39. Aykut-Yetkiner A., et al. “The effect of saliva substitutes on enamek erosion in vitro”. Journal of Dentistry 42 (2014): 720-725.
  40. Berman J and Sudbery PE. “Candida albicans: a molecular revolution built on lessons from budding yeast”. Nature Reviews Genetics 3 (2002): 918-931.
  41. Chen H., et al. “The regulation of hyphae growth in Candida albicans”. Virulence 11 (2020): 337-348.
  42. Chaffin WL., et al. “Candida albicans cell wall proteins”. Microbiology and Molecular Biology Reviews 72 (2008): 495-544.
  43. Modrzewska B and Kurnatowski P. “Adherence of Candida sp. to host tissues and cells as one of its pathogenicity features”. Annals of Parasitology 61 (2015): 3-9.
  44. Silva S., et al. “Candida glabrata, Candida parasitosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance”. FEMS Microbiology Reviews 36 (2012): 288-305.
  45. Naglik JR., et al. “Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections”. The Journal of Infectious Diseases 188 (2003): 469-479.
  46. Nobile CJ., et al. “Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo”. PLoS Pathogens 2 (2006): e63.
  47. Schaller M., et al. “The secreted Aspartyl Proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium”. Infection and Immunity 71 (2003): 3227-3234.
  48. Salerno C., et al. “Candida-associated denture stomatitis”. Medicna Oral, Patologia Oral y Cirugia Bucal 16 (2011): e139-143.
  49. Tobudic S., et al. “Antifungal susceptibility of Candida albicans in biofilm”. Mycoses 55 (2012): 199-204.

Kosuke Kataoka DDS, PhD., et al. “Effects of D-Psicose on Growth and Hyphal Development of Candida albicans” ”. EC Microbiology  19.9 (2023): 01-10.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net